Abstract
18F-fluorodeoxyglucose positron emission tomography/computed tomography has been used
in clinical practice for many years. This modality is of great value for tumour diagnosis,
staging, and efficacy evaluations, but it has many limitations in the diagnosis and
treatment of digestive system tumours. Fibroblast activation protein is highly expressed
in gastrointestinal tumours. Various isotope-labelled fibroblast activation protein
inhibitors are widely used in clinical research. These inhibitors have low background
uptake in the brain, liver and oral/pharyngeal mucosa and show good contrast between
the tumour and background, which makes up for the lack of fluorodeoxyglucose in the
diagnosis of digestive system tumours. It better displays the primary tumours, metastases
and regional lymph nodes of digestive system tumours, such as oesophageal cancer,
gastric cancer and liver cancer, and also provides a new method for treating these
tumours. Based on this background, this article introduces the current research status
of fibroblast activation protein inhibitor positron emission tomography/computed tomography
in various types of digestive system malignant tumours to provide more valuable information
for diagnosing and treating digestive system tumours.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; 71: 209-249
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; 68: 394-424
- Trends in esophageal adenocarcinoma incidence and mortality.Cancer. 2013; 119: 1149-1158
- Diagnosis and evaluation of gastric cancer by positron emission tomography.World J Gastroenterol. 2014; 20: 4574-4585
- (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer.Radiother Oncol. 2021; 158: 55-61
- Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review.Abdom Radiol. 2020; 45: 1018-1035
- (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer.J Nucl Med. 2019; 60: 801-805
- (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers.J Nucl Med. 2019; 60: 386-392
- Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma.J Thorac Dis. 2018; 10: 6066-6076
- Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: a meta-analysis.Medicine. 2018; 97: e13722
- [(68)Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer.Eur J Nucl Med Mol Imaging. 2020; 47: 3188-3189
- The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.J Nucl Med. 2009; 50: 1222-1228
- Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis.Nat Rev Gastroenterol Hepatol. 2013; 10: 203-205
- Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.PLoS ONE. 2015; 10e0116683
- A tumour-imaging method targeting cancer-associated fibroblasts.J Nucl Med. 2018; 59: 1423-1429
- Cancer associated fibroblasts in cancer pathogenesis.Semin Cell Dev Biol. 2010; 21: 33-39
- Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner.Cancer Cell. 2010; 17: 135-147
- Cancer-associated stromal fibroblasts promote pancreatic tumor progression.Cancer Res. 2008; 68: 918-926
- Cancer-associated fibroblasts and tumor growth–bystanders turning into key players.Curr Opin Genet Dev. 2009; 19: 67-73
- A stromal address code defined by fibroblasts.Trends Immunol. 2005; 26: 150-156
- The role of (68)Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience.J Nucl Med. 2020; 61: 1331-1336
- Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy.Proteom Clin Appl. 2014; 8: 454-463
- Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.Proc Natl Acad Sci U S A. 1994; 91: 5657-5661
- Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.Br J Clin Pharmacol. 2001; 51: 177-180
- Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis.J Nucl Med. 2015; 56: 778-783
- Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging.Molecules. 2015; 20: 2081-2099
- Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein.J Nucl Med. 2018; 59: 1415-1422
- Development of fibroblast activation protein-targeted radiotracers with improved tumour retention.J Nucl Med. 2019; 60: 1421-1429
- Selective inhibitors of fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.ACS Med Chem Lett. 2013; 4: 491
- Widespread metastatic gastric signet-ring cell carcinoma shown by 68Ga-FAPI PET/CT.Clin Nucl Med. 2021; 46: e78-e79
- (68)Ga FAPI PET/CT imaging in peritoneal carcinomatosis.Radiology. 2020; 297: 521
- Fibroblast imaging of hepatic carcinoma with (68)Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules.Eur J Nucl Med Mol Imaging. 2021; 48: 196-203
- Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients.J Nucl Med. 2020; 61: 1171-1177
- FAPI-74 PET/CT using either (18)F-AlF or Cold-Kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumour delineation in lung cancer patients.J Nucl Med. 2021; 62: 201-207
American Cancer Society (2017) Cancer facts & figures 2017.
- 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.Eur J Cancer. 2015; 51: 2545-2552
- Concurrent selective lymph node radiotherapy and S-1 plus cisplatin for esophageal squamous cell carcinoma: a phase II study.Ann Surg Oncol. 2019; 26: 1886-1892
- Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomised trial (RTOG 85-01). Radiation Therapy Oncology Group.Jama. 1999; 281: 1623-1627
- Fibroblast activating protein-α expression in squamous cell carcinoma of the esophagus in primary and irradiated tumors: the use of archival FFPE material for molecular techniques.Eur J Histochem. 2017; 61: 2793
- Tenascin-C, a prognostic determinant of esophageal squamous cell carcinoma.PLoS One. 2016; 11e0145807
- The superiority of [(68)Ga]-FAPI-04 over [(18)F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma.Eur J Nucl Med Mol Imaging. 2020; 48: 1248-1249
- Esophagogram and CT vs endoscopic and surgical specimens in the diagnosis of esophageal carcinoma.Radiol Med. 2002; 103: 344-352
- Impact of 18-fluorodeoxyglucose positron emission tomography on computed tomography defined target volumes in radiation treatment planning of esophageal cancer: reduction in geographic misses with equal inter-observer variability: PET/CT improves esophageal target definition.Dis Esophagus. 2010; 23: 493-501
- Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer.Mol Imaging Biol. 2020; 22: 1495-1500
- Evolving role of FDG-PET/CT in prognostic evaluation of resectable gastric cancer.World J Gastroenterol. 2017; 23: 6923-6926
- Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers.Radiology. 2021; 298: 393-402
- Imaging of gastric cancer metabolism using 18 F-FDG PET/CT.J Gastric Cancer. 2014; 14: 1-6
- (68)Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [(18)F] FDG PET/CT.Eur J Nucl Med Mol Imaging. 2021; 48: 647-648
- Cholangiocarcinoma: a guide for the nonspecialist.Int J Gen Med. 2019; 12: 13-23
- Hepatocellular carcinoma.Lancet. 2018; 391: 1301-1314
- Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.Ann Nucl Med. 2008; 22: 83-86
- Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET/CT versus MRI and [(18)F]-FDG PET/CT.Eur J Nucl Med Mol Imaging. 2020; 48: 1604-1617
- Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study.Eur J Nucl Med Mol Imaging. 2020; 48: 1593-1603
- Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a patient with cholangiocellular carcinoma: a case report.Clin Nucl Med. 2020; 45: 566-567
- A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic (68)Ga-FAPI-04 PET/CT imaging.EJNMMI Phys. 2021; 8: 8
- Tumour evolution in hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol. 2020; 17: 139-152
- Reply: [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer.Eur J Nucl Med Mol Imaging. 2020; 47: 2080-2082
- The superiority of [(68)Ga]Ga-FAPI-04 over [(18)F]-FDG in a case of neuroendocrine tumour with hepatic metastasis.Eur J Nucl Med Mol Imaging. 2021; 48: 3005-3006
- [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer.Eur J Nucl Med Mol Imaging. 2020; 47: 2078-2079
- 68Ga-FAPI PET/CT in assessment of liver nodules in a cirrhotic patient.Clin Nucl Med. 2020; 45: e430-e432
- Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.Pancreas. 2008; 37: 154-158
- Pancreatic adenocarcinoma.N Engl J Med. 2014; 371: 1039-1049
- Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.Strahlenther Onkol. 2014; 190: 485-490
- Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.Radiat Oncol. 2013; 8: 27
- Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma.Mol Med Rep. 2015; 11: 4585-4590
- Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance.World J Gastroenterol. 2012; 18: 840-846
- Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.BMC Gastroenterol. 2015; 15: 109
- Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma.JCI Insight. 2017; 2: e92232
- The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.Eur J Radiol. 2018; 106: 128-136
- A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.Ann Surg. 2009; 250: 957-963
- Impact of (68)Ga-FAPI-PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas.J Nucl Med. 2020; 62: 779-786
- Non-malignant findings of focal (68)Ga-FAPI-04 uptake in pancreas.Eur J Nucl Med Mol Imaging. 2021; 48: 2635-2641
- Intense FAPI uptake in inflammation may mask the tumour activity of pancreatic cancer in 68Ga-FAPI PET/CT.Clin Nucl Med. 2020; 45: 310-311
- Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer.Cancers. 2021; 13: 796
- Theranostics targeting fibroblast activation protein in the tumour stroma: (64)Cu- and (225)Ac-Labeled FAPI-04 in Pancreatic cancer xenograft mouse models.J Nucl Med. 2020; 61: 563-569
- Clinical implications of fibroblast activation protein in patients with colon cancer.Clin Cancer Res. 2007; 13: 1736-1741
- Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.Am J Pathol. 2011; 178: 1387-1394
- Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.J Exp Med. 2013; 210: 2851-2872
- Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer.Front Oncol. 2015; 5: 63
- Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.Proc Natl Acad Sci U S A. 1990; 87: 7235-7239
Article info
Publication history
Published online: August 04, 2021
Accepted:
July 14,
2021
Received in revised form:
July 12,
2021
Received:
March 7,
2021
Identification
Copyright
© 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
